Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has entered into collaboration and licensing agreement with MiNA Therapeutics for the development of novel treatments to treat fibrotic liver diseases.
Subscribe to our email newsletter
Under the deal, the partnership will use MiNA’s small activating RNA (saRNA) therapeutics platform to develop novel compounds for the treatment of fibrotic liver diseases such as NASH.
The companies intend to identify targets to restore metabolic functionality of hepatocytes and prevent fibrotic tissue formation in patients with NASH.
It will help Boehringer to design, profile and develop novel compounds, in addition to providing chance to combine with other NASH-pipeline assets.
As per terms of the deal, MiNA will secure an upfront payment and committed research funding from Boehringer.
The company will also secure potential research, development and regulatory milestone payments of up to €307m.
Boehringer produces a range of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension and cardio-renal risk reduction.
The company is also focusing more on developing novel drugs for the treatment of cardiometabolic diseases.
MiNA CEO Robert Habib said: “This collaboration is a recognition of our platform and expertise in liver-based diseases as well as validation from an established pharmaceutical leader in what has been an exciting year for the company.”
Boehringer Ingelheim discovery research corporate senior vice president Dr Clive Wood said: “This new collaboration is another sign of our ongoing commitment to patients with cardio-metabolic diseases, including NASH.
“It will combine MiNA’s pioneering work with saRNAs with our expertise in biopharmaceutical research and development.”